AbbVie's Migraine Drug Achieves Superiority In Preventing Headaches Compared To Generic Treatment In Head To Head Trial

Why is OpenAI dropping Scale AI as data provider? How will Microsoft’s planned job cuts impact sales? What caused Honda’s major US car recall? Why did Meta offer $100 million to poach AI staff? How will rising Middle East tensions affect oil prices? What does Nippon Steel’s US Steel acquisition mean? Why is the Fed holding interest rates steady now?

AbbVie's Migraine Drug Achieves Superiority In Preventing Headaches Compared To Generic Treatment In Head To Head Trial

benzinga.com/markets/large-cap/25/06/46001795/abbvies-migraine-drug-achieves-superiority-in-preventing-headaches-compared-to-generic-treatmen

AbbVie Inc (NYSE:ABBV) on Wednesday released topline results from its Phase 3 TEMPLE study evaluating the tolerability, safety, and efficacy of atogepant (QULIPTA/AQUIPTA, 60 mg once daily) compared to the highest tolerated dose of topiramate (50, 75 or 100 mg/day) in adult patients with…

This story appeared on benzinga.com, 2025-06-18 16:43:07.